Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Let the Market Decide

    One of the key points that came out of last week’s FOMC meeting was that Fed Chair Kevin Warsh wants the bond market to do more of the heavy lifting with regard to fighting inflation and promoting economic growth.

    Read more

  • NavVis Raises Series D Round Led by The Jordan Company

    William Blair acted as the sole and exclusive financial advisor to NavVis as it secures a $85M investment round, led by U.S. private equity firm The Jordan Company, as well as existing shareholders Yttrium (together with a consortium of industrial Family Offices), KOZO KEIKAKU ENGINEERING Inc., and Cipio Partners.

    Read more

  • Monthly Macro: China's Open-Weight Challenge and the Future of AI Economics

    William Blair macro analyst Richard de Chazal and group head of technology, media, and communications Arjun Bhatia examine how low-cost, open-weight AI models, many of them emerging from China, are reshaping competition across the AI ecosystem and challenging assumptions about the future economics of artificial intelligence.

    Listen to the podcast
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures